NCT03708328 2025-08-20A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid TumorsHoffmann-La RochePhase 1 Completed134 enrolled 37 charts
NCT04032704 2025-03-10A Study of Ladiratuzumab Vedotin in Advanced Solid TumorsSeagen Inc.Phase 2 Terminated205 enrolled 54 charts